[go: up one dir, main page]

AU2001238346A1 - Modification of biopolymers for improved drug delivery - Google Patents

Modification of biopolymers for improved drug delivery

Info

Publication number
AU2001238346A1
AU2001238346A1 AU2001238346A AU3834601A AU2001238346A1 AU 2001238346 A1 AU2001238346 A1 AU 2001238346A1 AU 2001238346 A AU2001238346 A AU 2001238346A AU 3834601 A AU3834601 A AU 3834601A AU 2001238346 A1 AU2001238346 A1 AU 2001238346A1
Authority
AU
Australia
Prior art keywords
biopolymers
modification
drug delivery
improved drug
improved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001238346A
Other languages
English (en)
Inventor
Pericles Calias
Robert J. Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AU2001238346A1 publication Critical patent/AU2001238346A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AU2001238346A 2000-02-15 2001-02-15 Modification of biopolymers for improved drug delivery Abandoned AU2001238346A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18255800P 2000-02-15 2000-02-15
US60182558 2000-02-15
US21150800P 2000-06-14 2000-06-14
US60211508 2000-06-14
PCT/US2001/004925 WO2001060412A2 (fr) 2000-02-15 2001-02-15 Modification de biopolymeres pour administration amelioree de medicaments

Publications (1)

Publication Number Publication Date
AU2001238346A1 true AU2001238346A1 (en) 2001-08-27

Family

ID=26878197

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001238346A Abandoned AU2001238346A1 (en) 2000-02-15 2001-02-15 Modification of biopolymers for improved drug delivery

Country Status (6)

Country Link
EP (1) EP1263472A2 (fr)
JP (1) JP2003522806A (fr)
AU (1) AU2001238346A1 (fr)
CA (1) CA2400205A1 (fr)
IL (1) IL151024A0 (fr)
WO (1) WO2001060412A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US20040043457A1 (en) * 2001-01-18 2004-03-04 Silke Schumacher Bifunctional fusion proteins with glucocerebrosidase activity
WO2004060404A1 (fr) * 2002-12-27 2004-07-22 Chugai Seiyaku Kabushiki Kaisha Vecteur de medicament
AU2004252091B2 (en) * 2003-06-05 2010-06-10 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
US7365223B2 (en) * 2003-06-18 2008-04-29 Nst Neurosurvival Technologies Ltd Method for selective targeting of apoptotic cells and small molecule ligands used thereof
EP1677848A2 (fr) * 2003-10-10 2006-07-12 Lui, Ge Ming Procedes et compositions pour accroitre des cellules endotheliales corneennes sur des polymeres et creer des greffons artificiels de la cornee
US7625736B2 (en) 2004-06-04 2009-12-01 The United States Of America As Represented By The Department Of Health And Human Services Methods for preparing immunogenic conjugates
TW200612991A (en) 2004-09-07 2006-05-01 Chugai Pharmaceutical Co Ltd Process for producing water-soluble hyaluronic acid modification
JP5137814B2 (ja) * 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するｐｅｇおよびポリシアルリソソーム酵素のコンジュゲート
WO2007008904A2 (fr) 2005-07-08 2007-01-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Ciblage de l'acide poly-gamma-glutamique en vue de traiter les infections provoquees par le staphylococcus epidermidis et les infections apparentees
ES2417146T3 (es) 2007-01-18 2013-08-06 Genzyme Corporation Oligosacáridos que comprenden un grupo aminoxi y conjugados de los mismos
HUE044381T2 (hu) 2008-12-16 2019-10-28 Genzyme Corp Szintetikus intermedierek oligoszacharid-fehérje konjugátumok elõállításához
JP6141180B2 (ja) 2011-03-03 2017-06-07 中外製薬株式会社 アミノ−カルボン酸により修飾されたヒアルロン酸誘導体
WO2012140650A2 (fr) 2011-04-12 2012-10-18 Hepacore Ltd. Conjugués de carboxy polysaccharides avec des facteurs de croissance des fibroblastes et variants de ceux-ci
US11564971B2 (en) 2012-09-05 2023-01-31 Chugai Seiyaku Kabushiki Kaisha Hyaluronic acid derivative having amino acid and steryl group introduced thereinto
KR102049568B1 (ko) * 2013-04-01 2019-11-27 삼성전자주식회사 히알루론산을 포함하는 핵산전달용 조성물
GB201602359D0 (en) * 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108440684A (zh) * 2018-03-22 2018-08-24 华侨大学 一种NI-Cys-Alg自组装纳米载体及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991014696A1 (fr) * 1990-03-29 1991-10-03 Gilead Sciences, Inc. Conjugues a base de disulfure d'oligonucleotide et d'un agent de transport
US5169934A (en) * 1990-05-14 1992-12-08 Anergen, Inc. Intracellularly cleavable compounds
US6335434B1 (en) * 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
WO1993008842A1 (fr) * 1991-11-08 1993-05-13 Somatogen, Inc. Hemoglobines utilisees comme agents administrateurs de medicaments
US5902795A (en) 1992-06-16 1999-05-11 Trustees Of Tufts College Oligosaccharides reactive with hyaluronan-binding protein and their methods of use
US5329029A (en) 1992-11-05 1994-07-12 Wan Barbara Y Phosphatidylalkanolamine derivatives and their use in generating phospholipid conjugates
BR9405798A (pt) * 1993-02-22 1995-12-12 Vivorx Pharmaceuticals Inc Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
US5354853A (en) 1993-03-12 1994-10-11 Genzyme Corporation Phospholipid-saccharide conjugates
AU734827B2 (en) * 1997-05-21 2001-06-21 Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
US5932552A (en) 1997-11-26 1999-08-03 Keraplast Technologies Ltd. Keratin-based hydrogel for biomedical applications and method of production

Also Published As

Publication number Publication date
IL151024A0 (en) 2003-02-12
WO2001060412A2 (fr) 2001-08-23
JP2003522806A (ja) 2003-07-29
CA2400205A1 (fr) 2001-08-23
WO2001060412A3 (fr) 2002-01-24
EP1263472A2 (fr) 2002-12-11

Similar Documents

Publication Publication Date Title
AU2001235009A1 (en) Drug delivery apparatus
AU2001269529A1 (en) Medicine comprising dicyanopyridine derivative
AU2001264887A1 (en) Drug delivery device
AU2001288388A1 (en) Substance delivery system
EP1455697A4 (fr) Administration de medicaments par voie vaginale
AU2002217979A1 (en) Medicine feeder
AU2001235691A1 (en) Use of paullone derivatives for making medicines
AU2001238346A1 (en) Modification of biopolymers for improved drug delivery
AU2002343555A1 (en) Eutectic-based self-nanoemulsified drug delivery system
AU2002353444A1 (en) Integrated transdermal drug delivery system
AU2001276860A1 (en) Medicaments for chemotherapeutic treatment of disease
AUPR573001A0 (en) Lymphatic drug delivery system
AU2001277171A1 (en) Catheter for target specific drug delivery
AU6887401A (en) Delivery of remotely-ordered products
AU2001232020A1 (en) Floating drug delivery composition
AU777185C (en) Pharmaceutical form of administration for peptides, methods for its production and use
AU2002360717A1 (en) Controlled release dosage form having improved drug release properties
AU2001270963A1 (en) Transdermal drug delivery system
AU2001232244A1 (en) Drug comprising combination
AU2001260089A1 (en) Pharmaceutical compositions comprising desglymidodrine as an active drug substance
AU2002308649A1 (en) Compositions and methods for enhancing drug delivery
AU3926000A (en) Methods and compositions for drug delivery
AU2002222138A1 (en) Drug delivery system
AU2002212863A1 (en) Stable pharmaceutical form of an anticancer drug
AU2001244854A1 (en) Local drug delivery